{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Theriva Biologics, Inc."},"Symbol":{"label":"Symbol","value":"TOVX"},"Address":{"label":"Address","value":"Maryland, 20850, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system."},"CompanyUrl":{"label":"Company Url","value":"https://www.therivabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Kaleko","title":"Senior Vice President-Research & Development"},{"name":"Steven A. Shallcross","title":"CEO, CFO, Treasurer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}